Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0Q3DV
|
||||
Former ID |
DNC014482
|
||||
Drug Name |
(+/-)-threo-Ritalinol methyl ether
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C14H21NO
|
||||
Canonical SMILES |
COCC(C1CCCCN1)C2=CC=CC=C2
|
||||
InChI |
1S/C14H21NO/c1-16-11-13(12-7-3-2-4-8-12)14-9-5-6-10-15-14/h2-4,7-8,13-15H,5-6,9-11H2,1H3/t13-,14-/m1/s1
|
||||
InChIKey |
DNWCZLGJLQABLG-ZIAGYGMSSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Sodium-dependent dopamine transporter | Target Info | Inhibitor | [1] | |
KEGG Pathway | Dopaminergic synapse | ||||
Parkinson's disease | |||||
Cocaine addiction | |||||
Amphetamine addiction | |||||
Alcoholism | |||||
PANTHER Pathway | Adrenaline and noradrenaline biosynthesis | ||||
Parkinson disease | |||||
Dopamine receptor mediated signaling pathway | |||||
Pathway Interaction Database | Alpha-synuclein signaling | ||||
Reactome | Na+/Cl- dependent neurotransmitter transporters | ||||
WikiPathways | Monoamine Transport | ||||
NRF2 pathway | |||||
Dopaminergic Neurogenesis | |||||
Parkinsons Disease Pathway | |||||
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
Neurotransmitter Clearance In The Synaptic Cleft | |||||
References | |||||
REF 1 | Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. Epub 2010 Aug 19.Quantitative structure-activity relationship studies of threo-methylphenidate analogs. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.